Clinical Trial Detail

NCT ID NCT02541604
Title A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors
Recruitment Terminated
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche

Advanced Solid Tumor

Hodgkin's lymphoma

non-Hodgkin lymphoma



Age Groups: child adult

No variant requirements are available.